Sustained HIV RNA suppression after switching from enfuvirtide to etravirine in the early access programme

J Antimicrob Chemother. 2009 Dec;64(6):1341-4. doi: 10.1093/jac/dkp366. Epub 2009 Oct 14.
No abstract available

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-HIV Agents / therapeutic use*
  • Antiretroviral Therapy, Highly Active / methods
  • Enfuvirtide
  • Female
  • HIV Envelope Protein gp41 / therapeutic use*
  • HIV Infections / drug therapy*
  • Humans
  • Male
  • Middle Aged
  • Nitriles
  • Peptide Fragments / therapeutic use*
  • Pilot Projects
  • Pyridazines / therapeutic use*
  • Pyrimidines
  • RNA, Viral / blood*
  • Treatment Outcome

Substances

  • Anti-HIV Agents
  • HIV Envelope Protein gp41
  • Nitriles
  • Peptide Fragments
  • Pyridazines
  • Pyrimidines
  • RNA, Viral
  • etravirine
  • Enfuvirtide